Acurx Pharmaceuticals (NASDAQ:ACXP - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.10) per share for the quarter.
Acurx Pharmaceuticals (NASDAQ:ACXP - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.80) by $0.60. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Acurx Pharmaceuticals Price Performance
NASDAQ:ACXP opened at $5.05 on Thursday. Acurx Pharmaceuticals has a 1-year low of $4.91 and a 1-year high of $47.80. The firm has a market cap of $7.78 million, a PE ratio of -0.36 and a beta of -1.27. The firm has a 50 day simple moving average of $8.76 and a 200-day simple moving average of $9.86.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $160.00 price objective on shares of Acurx Pharmaceuticals in a research note on Thursday, May 15th.
Get Our Latest Research Report on Acurx Pharmaceuticals
About Acurx Pharmaceuticals
(
Get Free Report)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Read More

Before you consider Acurx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acurx Pharmaceuticals wasn't on the list.
While Acurx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.